The norepinephrine transporter and pheochromocytoma

Annals of the New York Academy of Sciences

Volumn 1073, Issue , 2006, Pages 263-269

  Cleary, Susannah ^a,b   Phillips, Jacqueline K ^a  

^a MURDOCH UNIVERSITY   (Australia)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Cisplatin; Norepinephrine transporter; PC12 cells; Uptake assay

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; CISPLATIN; DOXORUBICIN; NORADRENALIN TRANSPORTER; SYNTAXIN 1A; TOPOTECAN;

ANALYSIS OF VARIANCE; CHROMAFFIN CELL; CONFERENCE PAPER; HUMAN; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; ISOTOPE LABELING; NEUROBLASTOMA; NEUROTRANSMISSION; NONHUMAN; PHENOTYPE; PHEOCHROMOCYTOMA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 33845485328     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1353.029     Document Type: Conference Paper

References (32)

1. BRYAN-LLUKA, L.J., N.N. WESTWOOD & S.R. O'DONNELL. 1992. Vascular uptake of catecholamines in perfused lungs of the rat occurs by the same process as Uptake1 in noradrenergic neurones. Naunyn Schmiedeberg's Arch. Pharmacol. 345: 319-326.
2. RAMAMOORTHY, S., P.D. PRASAD, P. KULANTHAIVEL, et al. 1993. Expression of a cocaine-sensitive norepinephrine transporter in the human placental syncytiotrophoblast. Biochemistry 32: 1346-1353.
3. CUBELLS, J.F., K.S. KIM, H. BAKER, et al. 1995. Differential in vivo regulation of mRNA encoding the norepinephrine transporter and tyrosine hydroxylase in rat adrenal medulla and locus ceruleus. J. Neurochem. 65: 502-509.
4. KIPPENBERGER, A.G., D.J. PALMER, A.M. COMER, et al. 1999. Localization of the noradrenaline transporter in rat adrenal medulla and PC12 cells: evidence for its association with secretory granules in PC12 cells. J. Neurochem. 73: 1024-1032.
5. PHILLIPS, J.K., R. DUBEY, E. SESIASHVILVI, et al. 2001. Differential expression of the noradrenaline transporter in adrenergic chromaffin cells, ganglion cells and nerve fibres of the rat adrenal medulla. J. Chem. Neuroanat. 21: 95-104.
6. SCHROETER, S., S. APPARSUNDARAM, R.G. WILEY, et al. 2000. Immunolocalization of the cocaine- and antidepressant-sensitive 1-norepinephrine transporter. J. Comp. Neurol. 420: 211-232.
7. HUYNH, T.T., K. PACAK, F.M. BROUWERS, et al. 2005. Different expression of catecholamine transporters in phaeochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. Eur. J. Endocrinol. 153: 551-563.
8. CLEARY, S., F.M. BROUWERS, G. EISENHOFER, et al. 2005. Expression of the noradrenaline transporter and phenylethanolamine N-methyltransferase in normal human adrenal gland and phaeochromocytoma. Cell Tissue Res. July: 1-11.
9. MAUREA, S., A. CUOCOLO, J.C. REYNOLDS, et al. 1993. Iodine-131- metaiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas: comparison with CT and MRI. J. Nucl. Med. 34: 173-179.
10. SHAPIRO, B., J.C. SISSON, B.L. SHULKIN, et al. 1995. The current status of metaiodobenzylguanidine and related agents for the diagnosis of neuro-endocrine tumors. Q. J. Nucl. Med. 39: 3-8.
11. SISSON, J.C. & B.L. SHULKIN. 1999. Nuclear medicine imaging of pheochromocytoma and neuroblastoma. Q. J. Nucl. Med. 43: 217-223.
12. PACAK, K., G. EISENHOFER, J.A. CARRASQUILLO, et al. 2001. 6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension 38: 6-8.
13. ILIAS, I., J. YU, J.A. CARRASQUILLO, et al. 2003. Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]- metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J. Clin. Endocrinol. Metab. 88: 4083-4087.
14. PACAK, K., W.M. LINEHAN, G. EISENHOFER, et al. 2001. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann. Int. Med. 134: 315-329.
15. 131I-MIBG): a comprehensive review of 116 reported patients. J. Endocrinol. Invest. 20: 648-658.
16. 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer 98: 239-248.
17. SAFFORD, S.D., R.E. COLEMAN, J.P. GOCKERMAN, et al. 2003. Iodine-131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery 134: 956-962.
18. SAFFORD, S.D., R.E. COLEMAN, J.P. GOCKERMAN, et al. 2004. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid: results in 98 patients. Cancer 101: 1987-1993.
19. ARMOUR, A., S.H. CUNNINGHAM, M.N. GAZE, et al. 1997. The effect of cisplatin pretreatment on the accumulation of MIBG by neuroblastoma cells in vitro. Br. J. Cancer 75: 470-476.
20. 131I]metaiodobenzylguanidine (MIBG) and cisplatin. Eur. J. Cancer 31A: 606-611.
21. 125I-meta-iodobenzylguanidine uptake in human neuroblastoma cell lines. Eur. J. Cancer 35: 1227-1234.
22. HARA, K., K. MINAMI, S. UENO, et al. 2002. Up-regulation of noradrenaline transporter in response to prolonged exposure to ketamine. Naunyn Schmiedebergs Arch. Pharmacol. 365: 406-412.
23. IKEDA, T., S. KITAYAMA, K. MORITA, et al. 2001. Nerve growth factor downregulates the expression of norepinephrine transporter in rat pheochromocytoma (PC12) cells. Brain Res. Mol. Brain. Res. 86: 90-100.
24. ORDWAY, G.A., W. JIA, J. LI, et al. 2005. Norepinephrine transporter function and desipramine: residual drug effects versus short-term regulation. J. Neurosci. Methods 143: 217-225.
25. ZHU, M.Y. & G.A. ORDWAY. 1997. Down-regulation of norepinephrine transporters on PC12 cells by transporter inhibitors. J. Neurochem. 68: 134-141.
26. ZHU, M.Y., S. SHAMBURGER, J. LI, et al. 2000. Regulation of the human norepinephrine transporter by cocaine and amphetamine. J. Pharmacol. Exp. Ther. 295: 951-959.
27. MCCLUSKEY, A.G., M. BOYD, M.N. GAZE, et al. 2005. [(131)I]MIBG and topotecan: A rationale for combination therapy for neuroblastoma. Cancer Lett. 228: 221-227.
28. ZAHNISER, N.R. & S. DOOLEN. 2001. Chronic and acute regulation of Na+/Cl-dependent neurotransmitter transporters: drugs, substrates, presynaptic receptors, and signaling systems. Pharmacol. Ther. 92: 21-55.
29. SUNG, U., S. APPARSUNDARAM, A. GALLI, et al. 2003. A regulated interaction of syntaxin 1A with the antidepressant-sensitive norepinephrine transporter establishes catecholamine clearance capacity. J. Neurosci. 23: 1697-1709.
30. EISENHOFER, G., J.W. LENDERS, W.M. LINEHAN, et al. 1999. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N. Engl. J. Med. 340: 1872-1979.
31. EISENHOFER, G., M.M. WALTHER, T.T. HUYNH, et al. 2001. Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J. Clin. Endocrinol. Metab. 86: 1999-2008.
32. DIXON, D.N., R.A. LOXLEY, A. BARRON, et al. 2005. Comparative studies of PC12 and mouse pheochromocytoma-derived rodent cell lines as models for the study of neuroendocrine systems. In Vitro Cell Dev. Biol. Anim. 41: 197-206.